v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Product revenue, net $ 8,720
Costs and expenses:    
Cost of sales 2,696
Research and development 9,555 9,941
Selling, general and administrative 19,502 9,786
Total costs and expenses 31,753 19,727
Loss from operations (23,033) (19,727)
Interest income 1,354 1,310
Interest expense (830) (998)
Change in fair value of warrant liabilities 5,386 7,245
Other income, net 50 141
Loss before income taxes (17,073) (12,029)
Income tax expense 2
Net loss $ (17,075) $ (12,029)
Basic loss per common share $ (0.30) $ (0.24)
Diluted loss per common share $ (0.30) $ (0.24)
Weighted average number of common shares outstanding - basic 56,620,920 49,778,801
Weighted average number of common shares outstanding - diluted 56,620,920 49,778,801
Other comprehensive loss:    
Change in unrealized losses related to available-for-sale debt securities $ (159) $ (75)
Comprehensive loss $ (17,234) $ (12,104)